Comparison of Immune Globulin Intravenous (Human), 10% (IVIG), plus Rituximab vs. IVIG 10% + Placebo (Normal Saline) as Agents to Reduce Donor Specific Antibodies, Improve Transplant Rates and Outcomes in Highly-HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

Grant

Date/time Interval

  • March 20, 2014 - March 21, 2014
  • Total Award Amount

  • 0.00
  • Direct Costs

  • 0.00
  • Sponsor Award Id

  • Contributor

  • Kumar, Vineeta   Investigator  
  • Locke, Jayme   Investigator  
  • Mannon, Roslyn   Principal Investigator  
  • Mehta, Shikha   Investigator